Moleculin Biotech
MBRX
MBRX
14 hedge funds and large institutions have $1.1M invested in Moleculin Biotech in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$119K | |
| 2 | +$32.1K | |
| 3 | +$26.4K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$11K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.83K |
Top Sellers
| 1 | -$1.64K | |
| 2 | -$1K | |
| 3 | -$162 | |
| 4 |
Wells Fargo
San Francisco,
California
|
-$112 |
| 5 |
JP Morgan Chase
New York
|
-$41 |